AbbVie is seeking accelerated approval for its cancer drug Teliso-V following positive data from a Phase 2 trial. If approved, the drug would be the first in its class approved for a certain type of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback